Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

All Impella Heart Pump Controllers Face Global Repair After Part Failures Tied to Three Deaths and 37 Injuries

Abiomed is removing all Automated Impella Controllers for part replacement after failures tied to three deaths. Here is what families should know.

Medical Daily

The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks

As Fed and inflation worries mount, Casey's General Stores, Johnson & Johnson, and PepsiCo stand out as defensive dividend payers with healthy balance sheets, growing payouts, and buyback programs.

MarketBeat

3 Healthcare Stocks for 3 Stages of Life

Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test

Ahead of CPI data and the Fed's rate decision, defensive stocks McDonald's, Johnson & Johnson, Walmart, Berkshire Hathaway, and NextEra Energy offer stability and dividends amid market uncertainty.

MarketBeat

Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?

Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.

Barchart

Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.

JNJ, MRK, and AMGN use AI to speed drug discovery, beat the market, and pay dividends. See the top AI healthcare pick for 2026.

Barchart

First Treatment Approved for the Rare Disease in Which Antibodies Destroy a Patient's Own Red Blood Cells

FDA approved Imaavy for warm autoimmune hemolytic anemia in patients 12 and older, the first therapy proven safe and effective for the disease.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?

Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.

MarketBeat

5 Stocks the Market Rewarded After Strong Earnings Results

Amazon, Microsoft, JPMorgan Chase, Johnson & Johnson and Coca-Cola posted strong earnings beats that held up, with cloud growth, capital returns and raised guidance fueling sustained stock gains.

MarketBeat

Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?

Johnson & Johnson has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

Barchart

First Thing: Pentagon accused of disrespecting war dead as Trump threatens to resume Iran war

Controversial move to classify Iran war as two separate campaigns criticised as attempt to minimise casualty figures. Plus, the man who started an animal shelter after a dog saved his life

The Guardian - UK

Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight

Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer

The Independent UK

Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today

Intuitive Surgical stock sinks as FDA announces marketing authorization for Johnson & Johnson’s Ottava platform. Here’s why the news is largely bearish for ISRG shares.

Barchart

5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama

While AI stocks correct, Johnson & Johnson, Altria, Coca-Cola, JPMorgan, and Apple are quietly trading near 52-week or all-time highs ahead of earnings.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Painful wait for women as unfounded claims delay payout

It could be another 12 months before a $405 million settlement for pelvic mesh injuries is fully paid out but the tidal wave of pain goes on for those hurt.

MarketBeat

Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

Barchart

3 Market-Beating Dividend Kings for Generations of Income

Three top-performing Dividend Kings combine decades of dividend growth with strong share-price gains and bullish analyst ratings.

Benzinga

TSMC Could Swing $150 Billion as Options Market Prices Big Moves for This Week’s Earnings

Earnings season kicks into high gear next week, with a slate of heavyweight companies set to report quarterly results between July 12 and July 18. As investors look for fresh insight into corporate earnings, guidance and the broader economic backdrop, options traders are already betting on how sharply these stocks…

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

‘This was a righteous case. A holy war’: the lawyer who took on Meta and Google – and won

When Mark Lanier and his young client Kaley faced the tech giants in an LA courtroom earlier this year, it seemed a bigger battle than David v Goliath. But they scored a landmark victory, proving that the social media giants had created ‘addiction machines’ that harmed mental health. How did…

The Economic Times

PepsiCo and more: Jim Cramer says market rotation is creating buying chances, picks 4 stocks

Jim Cramer said the latest market rotation has created attractive buying opportunities as institutional selling dragged down quality stocks. He highlighted PepsiCo, Starbucks, Constellation Brands, TJX Companies and Johnson & Johnson as potential picks despite recent market weakness.

International Business Times UK

MAGA Alliance Fractures Over Toxic Talc As Donald Trump Allegedly Abandons Asbestos Checks To Please Billionaire Execs

The FDA's withdrawal of a talc testing rule has intensified tensions between Trump's MAGA base and Kennedy's health movement, highlighting corporate influence and internal discord.

MarketBeat

These 3 Dividend Stocks Could Boost Your Income This July

Realty Income, Johnson & Johnson, and Chevron offer yields ranging from 2.2% to 5.1% in July 2026, supported by analyst buy ratings and institutional accumulation.

Barchart

Johnson & Johnson Earnings Preview: What to Expect

Johnson & Johnson is scheduled to report its second-quarter results next month, and analysts expect a single-digit earnings rise.

The Economic Times

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

MarketBeat

Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use

Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson. Chief Executive Of

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.